126 related articles for article (PubMed ID: 38782076)
1. Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics.
Li S; Song Z; Fan C; Zhang W; Ma T; Li X; Zhang Q; Zhao M; Yu T; Li S
Biochem Pharmacol; 2024 Jul; 225():116306. PubMed ID: 38782076
[TBL] [Abstract][Full Text] [Related]
2. Untargeted metabolomics analysis of the anti-diabetic effect of Red ginseng extract in Type 2 diabetes Mellitus rats based on UHPLC-MS/MS.
Yang Z; Dan Wang ; Li Y; Zhou X; Liu T; Shi C; Li R; Zhang Y; Zhang J; Yan J; Zhu X; Li Y; Gong M; Wang C; Yuan C; Cui Y; Wu X
Biomed Pharmacother; 2022 Feb; 146():112495. PubMed ID: 34891123
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
[TBL] [Abstract][Full Text] [Related]
5. Revealing hypoglycemic and hypolipidemic mechanism of Xiaokeyinshui extract combination on streptozotocin-induced diabetic mice in high sucrose/high fat diet by metabolomics and lipidomics.
Xiang Z; Xie H; Tong Q; Pan J; Wan L; Fang J; Chen J
Biomed Pharmacother; 2021 Mar; 135():111219. PubMed ID: 33433360
[TBL] [Abstract][Full Text] [Related]
6. UHPLC-MS-Based Serum and Urine Metabolomics Reveals the Anti-Diabetic Mechanism of Ginsenoside Re in Type 2 Diabetic Rats.
Wang H; Teng Y; Li S; Li Y; Li H; Jiao L; Wu W
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771066
[No Abstract] [Full Text] [Related]
7. Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.
Zarei M; Pujol E; Quesada-López T; Villarroya F; Barroso E; Vázquez S; Pizarro-Delgado J; Palomer X; Vázquez-Carrera M
Br J Pharmacol; 2019 Jul; 176(13):2292-2305. PubMed ID: 30927369
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice.
Zhang N; Liu C; Zhang Y; Xu D; Gui L; Lu Y; Zhang Q
Biochem Biophys Res Commun; 2021 Apr; 548():120-126. PubMed ID: 33640604
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
10. Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.
Liu J; Yang K; Yang J; Xiao W; Le Y; Yu F; Gu L; Lang S; Tian Q; Jin T; Wei R; Hong T
EBioMedicine; 2019 Mar; 41():73-84. PubMed ID: 30827929
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics-based evidence of the hypoglycemic effect of Ge-Gen-Jiao-Tai-Wan in type 2 diabetic rats via UHPLC-QTOF/MS analysis.
Wang W; Zhao L; He Z; Wu N; Li Q; Qiu X; Zhou L; Wang D
J Ethnopharmacol; 2018 Jun; 219():299-318. PubMed ID: 29580854
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption.
Li S; Wang N; Guo X; Li J; Zhang T; Ren G; Li D
Biomed Pharmacother; 2018 Dec; 108():355-366. PubMed ID: 30227329
[TBL] [Abstract][Full Text] [Related]
13. Interventional effects of Pueraria oral liquid on T2DM rats and metabolomics analysis.
Yang HB; Song JY; Xu C; Li J; Zhang C; Xie S; Teng CL
Biomed Pharmacother; 2024 Jun; 175():116780. PubMed ID: 38781864
[TBL] [Abstract][Full Text] [Related]
14. Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus.
Guo C; Zhao L; Li Y; Deng X; Yuan G
J Cell Physiol; 2021 Jan; 236(1):55-67. PubMed ID: 32583417
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization and
Al-Zuaidy MH; Mumtaz MW; Hamid AA; Ismail A; Mohamed S; Razis AFA
BMC Complement Altern Med; 2017 Jul; 17(1):359. PubMed ID: 28693595
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycemic effects of
Liu N; Chen X; Song J; Chen M; Gong P; Jia W; Li G
Food Funct; 2021 Oct; 12(20):9994-10007. PubMed ID: 34505615
[TBL] [Abstract][Full Text] [Related]
17. FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction.
Diener JL; Mowbray S; Huang WJ; Yowe D; Xu J; Caplan S; Misra A; Kapur A; Shapiro J; Ke X; Wu X; Bose A; Panza D; Chen M; Beaulieu V; Gao J
Endocrinology; 2021 Sep; 162(9):. PubMed ID: 33951176
[TBL] [Abstract][Full Text] [Related]
18. Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway.
Yu D; Ye X; Wu Q; Li S; Yang Y; He J; Liu Y; Zhang X; Yuan Q; Liu M; Li D; Ren G
Endocrine; 2016 Jun; 52(3):527-40. PubMed ID: 26607153
[TBL] [Abstract][Full Text] [Related]
19. Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.
Hecht R; Li YS; Sun J; Belouski E; Hall M; Hager T; Yie J; Wang W; Winters D; Smith S; Spahr C; Tam LT; Shen Z; Stanislaus S; Chinookoswong N; Lau Y; Sickmier A; Michaels ML; Boone T; Véniant MM; Xu J
PLoS One; 2012; 7(11):e49345. PubMed ID: 23209571
[TBL] [Abstract][Full Text] [Related]
20. Dynamic change of serum FGF21 levels in response to glucose challenge in human.
Lin Z; Gong Q; Wu C; Yu J; Lu T; Pan X; Lin S; Li X
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1224-8. PubMed ID: 22539584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
